Entellus Medical, which sells a minimally invasive treatment to open obstructed sinus pathways, raised $78 million by offering 4.6 million shares (up from 4.4 million) at $17, the high end of the range of $15 to $17. Entellus Medical plans to list on the NASDAQ under the symbol ENTL. Entellus Medical initially filed confidentially on 10/7/2014. BofA Merrill Lynch and Piper Jaffray acted as lead managers on the deal.
